Podcasts about zepbound

Doctor Mau Informa ®️#drmauinforma 

2025: The Year America Got Thinner — But Not Healthier | Media Power Grabs & Cancer Truths 2025 is being called “the year America shed” — with more people losing weight than ever thanks to fad diets, Ozempic, Wegovy, Zepbound, and every quick-fix trend imaginable. But here's the shocking truth: Americans may be getting thinner, but not healthier. Why? Today we break down the real reasons behind the wellness illusion. Then, a massive story almost no one is paying attention to: the brewing Warner Bros. takeover battle. Donald Trump, backed by Saudi money and his son-in-law Jared Kushner, is pushing for a hostile takeover to compete with (and control) Netflix. What's the motive? What does it mean for media, entertainment, and democracy? We dig into the power dynamics behind the scenes. Plus — new, surprising research on cancer detection asks a provocative question: Should all cancers be found? The answer isn't what you think. The Karel Cast is funded by your support at patreon.com/reallykarel. Watch, like, comment, and subscribe at youtube.com/reallykarel. Listen on all major platforms: Apple Music, Spotify, iHeartMedia, Spreaker, and more. Catch the show Monday through Thursday at 10:30 AM PST, with daily clips on TikTok and Instagram. Karel is a history-making broadcaster based in Las Vegas with his service girl, Ember — bringing bold commentary, big stories, and unfiltered truth. #TheKarelCast, #2025Trends, #OzempicCulture, #WeightLossTruth, #Wegovy, #Zepbound, #AmericanHealthCrisis, #MediaTakeover, #WarnerBrosDeal, #TrumpNews, #JaredKushner, #SaudiMoney, #NetflixWar, #CancerResearch, #HealthMyths, #PoliticalCommentary, #NewsAnalysis2025, #LasVegasCreator, #LGBTQCommentator, #PodcastLife https://youtube.com/live/NPftX-i5_EU

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We share a quick life update, welcome our first guest Mike Rozanski, and clear up the Michelin Guide origin story before shifting to a focused guide on starting GLP-1 medications. Practical strategies cover injections, nausea, constipation, muscle protection, and adjusting other meds safely.• board certification in obesity medicine and motivation to destigmatise care• guest segment on Michelin guide history and Philly's recent stars• what GLP-1 meds are and how auto-injectors work• portion sizing to prevent nausea and early side effects• fiber with fluids to prevent constipation• protein targets and simple strength training to protect muscle• when to adjust blood pressure and diabetes medications• key takeaways and encouragement to start small and follow upIf you found this helpful, a review really does go a long way for a like on whatever app you're listening to us onSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you're over 60 and using GLP-1 medications like Wegovy or Zepbound, this episode could save your independence. In this episode, I reveal the hidden danger of rapid weight loss without muscle protection—and the simple strategies that keep you strong, steady, and mobile as the pounds come off. GLP-1 medications are transforming weight loss for older adults managing diabetes, high blood pressure, and joint pain. But there's a critical piece most people miss: sarcopenia. This age-related muscle loss accelerates during weight loss, putting you at risk for falls, fractures, and losing the strength you need for daily activities. Tune in to learn how to lose weight safely while protecting the muscle that keeps you independent—and why strength training, protein intake, and staying active aren't optional on this journey.   Episode Highlights: Why GLP-1 medications like Wegovy and Zepbound are game-changers for adults 60+ The connection between muscle loss, falls, fractures, and loss of independence How sarcopenia affects metabolism, blood sugar control, and bone health Protein requirements for older adults (25-30 grams per meal) Simple strength training routines you can do at home—no gym required Red flags that muscle loss is happening too fast Real patient story: turning weakness into strength on a GLP-1 journey   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In one of our most eye-opening conversations yet, Bo Brabo and Luke Carignan sit down with clinical pharmacist Langley Kyle to unpack the truth behind GLP-1 medications—Wegovy, Ozempic, Zepbound, tirzepatide, and their compounded counterparts. Whether you're an HR leader, benefits strategist, or simply trying to understand why GLP-1s dominate workplace conversations, this episode breaks it all down with clarity, expertise, and a surprising amount of laughter.From skyrocketing utilization to social-media-driven demand, Langley reveals what she's seeing across employer plans nationwide…and what's coming next.

Winner of the CTP Cup for IBIT Announcing the participants for the CTP Cup 2025 Calling a Code Red! Sam Altman’s declaration PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Winner of the CTP for IBIT - Announcing the participants for the CTP Cup 2025 - Calling a Code Red! Sam Altman's panic - Here come the Tariff lawsuits - - Smart Toilets are a thing (And learning the Bristol Scale) Markets - Horses can smell the barn.... Seasonal Trends - PR Teams - full throttle - (This is their Social Media) - Tax planning over the next couple of weeks may see some selling into year end Impressive Results - India's economy grew at a faster-than-expected pace of 8.2% in the quarter ended September against a forecast of 7.3% in a Reuters poll and 7.8% expansion in the previous quarter, data released last Friday showed. - The Indian government has cut consumer taxes on hundreds of items and implemented long-delayed labour reforms in the last three months as it tries to keep the domestic economy strong in the face of global uncertainties. - Strongest in 6 quarters - Economists said stockpiling for the festive season as well as expedited exports ahead of the 50% tariff deadline on August 27 might have contributed to the quarterly growth figures. - Manufacturing output rose 9.1% in the quarter ending in September from a year earlier against growth of 7.7% a quarter ago, while construction expanded 7.2% year-on-year from 7.6% a quarter ago. NVDA Spreading Out - Nvidia on Monday announced it has purchased $2 billion of Synopsys common stock as part of a strategic partnership to accelerate computing and artificial intelligence engineering solutions. - As part of the multiyear partnership, Nvidia will help Synopsys accelerate its portfolio of compute-intensive applications, advance agentic AI engineering, expand cloud access and develop joint go-to-market initiatives, according to a release. - Nvidia said it purchased Synopsys' stock at $414.79 per share (Now at $445) Amazon Ultra Fast Service - The parent company of Instacart fell nearly 4% after Amazon said it's testing “ultra-fast” delivery of groceries in Seattle and Philadelphia. - These deliveries take about 30 minutes or less, said Amazon. - Doordash and other delivery companies stocks also fell. Microstrategy - Strategy - Stock has been under pressure - Who knows what the company actully does anymore - Leverage Bitcoin play - issuing massive debt and convertibles to but Bitcoin - Stock down 39% this year and 52% 1 -year (Up 400% in the last 5 years) -Bitcoin dropped below $87k this week before staging a recovery bounce. Devil's Metal - Silver has outpaced gold in 2025, with a growth of about 71%, compared to gold's 54%. - Silver mine production has been decreasing for the past ten years, especially in Central and South America, due to mine closures, resource depletion and infrastructure challenges. - While industrial demand for silver is expected to decline slightly in 2025, the metal is increasingly used in electric vehicles, for AI components and in photovoltaics. - Some people are saying that people were having to transport silver by plane rather than on cargo ships to meet delivery demand INTERACTIVE BROKERS Check this out and find out more at: http://www.interactivebrokers.com/ Some Trump Updates: - Reiterates his view that Chair Powell should reduce rates. - Says he's negotiating with Democrats on healthcare. - Plans to give refunds out of collected tariffs. Crying Game - SoftBank Group founder Masayoshi Son on Monday downplayed the decision to offload the conglomerate's entire Nvidia stake, saying he “was crying” over parting with the shares. - Speaking at a forum in Tokyo Monday, Son addressed SoftBank's November disclosure that the firm had sold its holding in the American chip darling for $5.83 billion. - According to Son, SoftBank wouldn't have made the move if it didn't need to bankroll its next artificial intelligence investments, including a big bet on OpenAI and data center projects. Are Stocks Overvalued? CAPE RATIO Consumers... Consumer Confidence CODE RED -  Chief executive Sam Altman reportedly declared a “code red” on Monday, urging staff to improve its flagship product ChatGPT, an indicator that the startup's once-unassailable lead is eroding as competitors like Google and Anthropic close in. - In the memo, reported by the Wall Street Journal and The Information, Altman said the company will be delaying initiatives like ads, shopping and health agents, and a personal assistant, Pulse, to focus on improving ChatGPT. This includes core features like greater speed and reliability, better personalization, and the ability to answer more questions, he said. - Herein lies the problem with this entire tech market - what if ChatGPT fades to the sideline with $1.5Trillion promised over the next 5-7 years? - Remember, Google declared a Code Red after the arrival of ChatGPT. AI Takeover - Massachusetts Institute of Technology on Wednesday released a study that found that artificial intelligence can already replace 11.7% of the U.S. labor market, or as much as $1.2 trillion in wages across finance, health care and professional services. - The study was conducted using a labor simulation tool called the Iceberg Index, which was created by MIT and Oak Ridge National Laboratory. - The index simulates how 151 million U.S. workers interact across the country and how they are affected by AI and corresponding policy. Costco Sues - Costco filed a lawsuit asking for a full refund of tariffs the warehouse club giant has paid since President Donald Trump imposed “reciprocal” and “fentanyl” tariffs earlier this year. - Costco sued the Trump administration to get a full refund of new tariffs it paid so far this year, and to block those import duties from continuing to be collected from the retail warehouse club giant as a Supreme Court case plays out. - Costco is worried that it would lose the money even if the Tariffs were deemed illegal. Fat Cutting -  Eli Lilly said it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug Zepbound on its direct-to-consumer platform, LillyDirect. - Starting Dec. 1, cash-paying patients with a valid prescription can pay $299 to $449 per month for Zepbound vials on LillyDirect, depending on the dose, down from a previous range of $349 to $499 per month. - The announcement comes just weeks after President Donald Trump inked deals with Eli Lilly and Novo Nordisk to make their GLP-1 drugs easier for Americans to access and afford. Smart Toilets - This year industry giants Toto Ltd. and Kohler Co. introduced smart toilets capable of analyzing what is in the bowl - Launched in August, the latest model in the Neorest line starts at roughly $3,200. - It uses an LED light and a sensor to read the shape, color, hardness and volume of stool as it drops, and sends data to a smartphone app in less than a minute. - Each toilet can support as many as six users — enough for most households — while some companies have bought multiple units for their employees. Toto aims to sell 7,300 units annually by 2028. - For now the stool-scanning Neorest is available only in Japan. - The app analyzes bowel movements against the Bristol scale, which is commonly used to diagnose constipation, inflammation or diarrhea, and offers simple recommendations such as eating more fiber and drinking more water, or even menu suggestions, like vegetable soup. Bristol Scale Feel Good - Entrepreneur Michael Dell and his wife, Susan, will deposit $250 in the individual investment accounts of 25 million American children in a $6.25 billion philanthropic pledge as part of the Trump administration's Invest America initiative. - $250 each child born after between 2015 and 2025 - The money will go to the accounts of children who live in ZIP codes where the median family's income is $150,000 or less, according to a spokesperson for the Dells. Love the Show? Then how about a Donation? Announcing the Winner for iShares Bitcoin Trust ETF (IBIT) Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt! CTP CUP 2025 Here is the list of players: Jim Beaver Mike Kazmierczak Joe Metzger Ken Degel David Martin Dean Wormell Neil Larion Mary Lou Schwarzer Eric Harvey (2024 Winner) FED AND CRYPTO LIMERICKS See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Popular GLP-1 medications like Ozempic, Wegovy, and Zepbound aren’t just transforming weight loss. They’re also changing our intimate lives in surprising ways. In today’s show, we’re diving into results from a new national study finding that a majority of people taking one of these medications reported a change in their sex and dating lives, for better or for worse. My guest is Dr. Amanda Gesselman a research scientist and head of the VIBES research team at the Kinsey Institute at Indiana University. Digital intimacy is a major focus of her research, including how people use tools like camsites, AI companions, dating apps, and social media to navigate connection and desire. Some of the specific topics we explore in this episode include: What specific changes are people noticing in their dating lives as a result of taking one of these drugs? Why does weight loss seem to be benefiting men more than women when it comes to dating? How do GLP-1 medications affect sexual health and function? And is it different for men and women? Are people taking GLP-1 medications worried about social judgement? To learn more, you can read a brief report about the study here. Got a sex question? Send me a podcast voicemail to have it answered on a future episode at speakpipe.com/sexandpsychology. *** Thank you to our sponsors!  Firmtech’s Tech Ring will help you to track your sexual health–and keep it up. Visit myfirmtech.com/justinlehmiller and use code JUSTIN15 for 15% off your purchase.  The Kinsey Institute is where the world turns to understand sex and relationships. You can help continue its expert-led research by donating to the Kinsey Institute Research Fund. Learn more and make a donation here: https://give.myiu.org/centers-institutes/I380010749.html  *** Want to learn more about Sex and Psychology? Click here for previous articles or follow the blog on Facebook, Twitter, or Bluesky to receive updates. You can also follow Dr. Lehmiller on YouTube and Instagram. Listen and stream all episodes on Apple, Spotify, or Amazon. Subscribe to automatically receive new episodes and please rate and review the podcast! Credits: Precision Podcasting (Podcast editing) and Shutterstock/Florian (Music). Image created with Canva; photos used with permission of guest.

The cozy, magical season is here! Leggings, sweaters, cookies, hibernation mode. But this can also become the season where we disconnect from our bodies without even realizing it.In this episode, I'm sharing a truth we don't talk about enough:✨ The longer you hide in leggings and oversized sweatshirts, the longer you stay in denial about where you really are physically and emotionally. ✨ Getting dressed, putting on makeup, and wearing a real outfit isn't about vanity… it's about awareness, identity, and showing up for yourself. ✨ And what I don't want is for you to “wake up” in spring only to realize nothing fits and you don't recognize yourself.Let's talk about how you can stay connected, confident, and present with yourself even during cozy season so you don't lose yourself in the process.

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore the latest advances and strategic moves shaping the industry, providing you with insights into how these developments might influence drug development and patient care.The pharmaceutical and biotech sectors are currently experiencing a wave of transformative changes. A significant development is the trade agreement between the United States and the United Kingdom, which excludes medicines from import tariffs. This strategic move, orchestrated by the Trump administration, is set to reduce costs and bolster investments in pharma sectors across both nations. By enhancing market accessibility, it aims to stimulate cross-border investment in pharmaceutical research and production.On the clinical front, Eli Lilly is making headlines by joining Novo Nordisk in reducing self-pay prices for its GLP-1 receptor agonist, Zepbound. This reflects a broader industry trend towards patient-centric pricing models aimed at improving affordability. With healthcare costs on the rise, these measures could ease financial burdens for patients requiring long-term medication regimens.Regulatory updates are also making waves, with the FDA planning stricter vaccine regulations under Dr. Vinay Prasad's leadership at the Center for Biologics Evaluation and Research (CBER). These updates come amid concerns over vaccine safety during COVID-19-related incidents, underscoring a commitment to maintaining public trust in vaccines. Regulatory scrutiny continues as Prasad focuses on COVID-19 vaccine safety in children amid reports linking 10 child deaths to vaccines via VAERS—emphasizing challenges interpreting safety data while highlighting the need for robust methodologies ensuring reliable causality conclusions.In corporate restructuring news, Valneva is streamlining its operations by closing a site and eliminating 30 roles. This move highlights an industry focus on optimizing resources to bolster vaccine development pipelines. Meanwhile, Microsize and Schedio's acquisition of Lonza's Swiss micronization plant underscores ongoing investments in advanced manufacturing technologies critical for high-quality pharmaceuticals.In ophthalmology, Belite Bio is advancing with promising Phase 3 results for tinlarebant in treating Stargardt disease—a rare genetic eye disorder. This success positions Belite to file for FDA approval, potentially expanding treatment options for this underserved patient population. Such advancements in targeted therapies emphasize the need for ongoing research in genetic disorders.Regeneron is betting $150 million on Tessera's gene writing technology targeting alpha-1 antitrypsin deficiency (AATD). This collaboration highlights the industry's growing interest in gene therapy as a frontier for treating rare diseases, marking a shift towards precision medicine where tailored genetic interventions offer hope for previously untreatable conditions. Regeneron's strategic move investing $275 million partnering with Tessera exploring gene editing capabilities—focusing on TSRA-196 targeting the SERPINA1 gene linked to AATD showcases potential advancing therapeutic options for genetic disorders through gene editing technologies offering new disease treatment avenues.AI-driven platforms were spotlighted at RSNA 2025 by industry leaders such as GE Healthcare, Philips, and Siemens. These innovations promise to revolutionize radiological workflows by enhancing diagnostic accuracy and operational efficiency through AI integration. As AI continues to permeate healthcare technologies, its potential to transform diagnostic processes marks a significant leap towards personalized medicine.Akebia Therapeutics' acquisition ofSupport the show

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Monday Headline Brief of The Wright Report, Bryan covers the nation's grief and anger after the Washington terror attack, the deepening crisis within America's immigration system, and President Trump's most sweeping border actions yet. He also examines the political backlash, the debate over assimilation, and the global pressures shaping events from Europe to Venezuela. America Mourns and Demands Answers: Staff Sgt. Andrew Wolfe remains in critical condition while Specialist Sarah Beckstrom is laid to rest after last week's terror attack in Washington. DHS confirmed the attacker, Rahmanullah Lakanwal, was a former CIA-backed Afghan Zero Unit fighter who was radicalized after arrival in the United States. Investigators say he drifted between Washington State, Arizona, and the East Coast with little oversight, revealing systemic vetting failures across multiple administrations.   Vetting Breakdown Exposed: Inspector General reports show that over two hundred thousand Afghans brought into the country during the 2021 evacuation were admitted with almost no reliable databases, poor ID verification, and limited interagency cooperation. None received continual vetting after entry. Bryan explains why "strict vetting" is a political myth and why U.S. systems remain unable to verify criminal history, ideology, or cultural fit for many migrants.   Trump Orders the Most Sweeping Immigration Freeze in Decades: The President has paused all asylum applications, halted Afghan visa processing, and instructed his team to permanently pause migration from Third World nations to reset the system. Green card and citizenship requests from nineteen countries are suspended. Trump is also considering the denaturalization of foreign-born citizens who fail loyalty or cultural compatibility standards. Legal scholars note that Section 212(f) of the Immigration and Nationality Act grants the President broad authority to take such steps.   Political Firestorm and Cultural Divide: Republicans and most Independents support a historic crackdown, while Democrats accuse Trump of racism and xenophobia. Some leaders, including Representative Jasmin Crockett and Representative Debbie Wasserman Schultz, blamed the National Guard deployments for the attack. Bryan argues that many progressive lawmakers reject assimilation because they reject the idea of American culture itself, pointing to recent examples in education, media, and politics.   College Degrees Lose Appeal: New polling shows only 33 percent of Americans believe a four-year degree is worth the cost. Interest in vocational training and maritime careers is rising as tuition increases outpace wages. Maritime academies report that graduates earn more than $200,000 a year after six months of work.   The Autopen Controversy: President Trump announced he is canceling all executive actions signed by Joe Biden through the autopen, citing concerns that Biden did not authorize their use. The Justice Department may soon bring cases that will force the Supreme Court to clarify the legality of autopen approvals.   Debate Over Unlawful Orders Heats Up: Reports claim Secretary of War Pete Hegseth ordered a second strike on a cartel boat. Hegseth denies it. Senator Mark Kelly suggested troops should rely on intuition when evaluating orders, which critics warn could lead to chaos and politicized discipline. The issue may shape U.S. operations in the Caribbean.   Global Flashpoints: Venezuela and Europe: Trump rejected demands from Venezuela's Nicolás Maduro for guaranteed amnesty and military control as part of an exit deal. Maduro may attempt a guerrilla resistance if forced out. In Europe, Islamist protests are disrupting Christmas markets in Belgium and Germany, where security costs have surged. France's populist movement is surging in polls as crime tied to migrants fuels public frustration. Portugal's populist party Chega is also now tied for first place in national polling.   Medical News: A major UK study finds that weight loss drugs like Mounjaro and Zepbound must be taken long-term to maintain results, with many patients regaining most of the weight after stopping treatment.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Washington DC terror attack Afghan Zero Unit, Rahmanullah Lakanwal vetting failure, Trump asylum freeze Section 212f, de-naturalization debate immigration reform, Jasmin Crockett Guard criticism, Debbie Wasserman Schultz Trump blame, college degree value drop vocational training, autopen Biden executive actions, Hegseth double tap allegation, Venezuela Maduro exit talks, Belgium Germany Christmas market threats, France National Rally Bardella, Portugal Chega Ventura, GLP-1 weight loss drug study UK

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Should I take a GLP-1? Real Patient Scenarios and Expert GuidanceTrying to figure out if a GLP-1 medication is right for you can feel overwhelming. With options like Wegovy, Zepbound, Ozempic, and Mounjaro, it's not just about weight—these medications can also support heart health, liver function, sleep, and blood sugar. Understanding who truly benefits takes the guidance of an expert.Joining me today is Danielle Marston, or Dani, a board-certified nurse practitioner specializing in obesity medicine, weight management, and nutrition counseling. Dani holds a certificate of advanced education in obesity medicine through the Obesity Medicine Association and provides comprehensive care at our clinic, Colorado Wake Care at Green Mountain Partners for Health. She's here to explain how GLP-1s work, their benefits, and who they can help the most.Through real patient scenarios and practical advice, Dani shows how obesity care can be personalized, evidence-based, and approachable.Whether you're curious about starting a GLP-1, considering other treatment options, or just trying to understand what's available, this episode gives you a clear roadmap to make informed decisions and find a plan that actually fits your life.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Dr. Emily Cooper, Mark Wright, and Andrea Taylor talk with Maria from Buffalo, a longtime listener who shares her lifelong journey with obesity, psoriatic arthritis, and binge eating—and how finally understanding the science of metabolism gave her hope. Maria describes early childhood weight gain, joint damage, and years of restrictive dieting and food shame, then explains how GLP‑1 therapy (Zepbound) plus mechanical eating helped her lose about 50 pounds while eating more food, more often, and with more joy. Dr. Cooper breaks down the underlying biology—leptin, weight set point, the melanocortin pathway, and the impact of pain, sleep, and chronic inflammation on hunger hormones—and reframes obesity as a symptom of deeper metabolic problems, not a character flaw. This episode doubles as a practical, emotionally honest guide for patients trying to navigate a traditional health‑care system without a dedicated metabolic specialist.Key Questions AnsweredHow can rapid childhood weight gain, autoimmune disease, and early joint damage signal serious metabolic dysfunction rather than “too much food” or “not enough exercise”?What is leptin, what does “too low for your size” mean, and how does that affect hunger, weight set point, and weight loss?What is monogenic obesity testing, who might qualify for free genetic screening, and how can results inform (but not necessarily change) treatment?How do GLP‑1 medications like Zepbound work with mechanical eating so someone can lose weight while eating more regularly and with more variety?Which labs (fasting glucose, insulin, leptin, etc.) help uncover hidden metabolic issues, and when is a mixed‑meal test more useful than a simple fasting snapshot?When should brain‑active medications (such as bupropion/naltrexone combinations) be considered, and what trade‑offs and side effects matter?How can patients respectfully push for tests, challenge old “eat less, move more” advice, and set boundaries around weigh‑ins and stigmatizing language?Key TakeawaysIt's not your fault: Rapid childhood weight gain and early‑onset obesity often reflect serious metabolic biology, including rare gene variants, growth phases, and hormone signaling—not gluttony or laziness.Obesity is a symptom: Excess weight is better understood as a side effect of underlying metabolic fires (leptin issues, insulin resistance, brain signaling problems) that need proper diagnosis and treatment.Leptin really matters: Low leptin for your size can act as a biological brake on weight loss, and chronic dieting, under‑fueling, over‑exercise, and some high‑dose supplements can suppress it further.GLP‑1s plus mechanical eating: Medications like Zepbound can quiet food noise and support weight loss, but scheduled, balanced eating is essential to avoid under‑fueling, protect muscle, and support hormones.Pain and sleep are metabolic: Chronic pain and poor sleep increase hunger hormones like ghrelin and disrupt repair processes, worsening metabolic dysfunction unless directly addressed.Script your visits: Bring a printed list of diagnoses, medications, and questions; use patient portals to request specific tests; and practice simple boundary phrases around weighing and diet talk.Notable Quote“This isn't all just caused by diets and things like that. There was an original metabolic problem. It was amplified because of the food restriction and the psychology around it, but you are a product of cumulative insults to your system—not a moral failure.” — Dr. Emily CooperLinks & ResourcesPodcast Home: https://fatsciencepodcast.com/Cooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources and education from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.comFat Science is informational only and does not constitute medical advice.

✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Send us a message with this link, we would love to hear from you. Standard message rates may apply.We unpack new GLP-1 pricing, coverage hurdles, and whether cash-pay programs make these meds more reachable for diabetes, obesity, and sleep apnea care. Along the way we share candid pros and cons of injections, tease future oral options, and weigh real tradeoffs.• current cash-pay pricing from major manufacturers• differences between Wegovy, Ozempic, and Zepbound• tighter insurance coverage and prior authorization burden• fears about injections and route-of-administration bias• potential oral GLP-1 timelines and cost impact• framing obesity as a chronic, treatable disease• practical tips to explore HSA or FSA options• how to decide if the monthly cost is worth itSupport the showSubscribe to Our Newsletter! Production and Content: Edward Delesky, MD & Nicole Aruffo, RNArtwork: Olivia Pawlowski

If you've been waiting for a GLP-1 weight loss medication that doesn't require injections, special timing, or refrigeration—this episode is for you. Learn about the groundbreaking oral pill that could hit the market as early as 2026. For years, effective obesity medications have meant needles. But Orforglipron could change everything. In this episode, I break down the science, clinical trial results, and approval timeline for this first-of-its-kind once-daily pill that delivers GLP-1 benefits without the injection barriers. Whether you're needle-averse, struggle with injection site reactions, or simply want more convenient options, this new medication could expand access to life-changing obesity treatment.   Episode Highlights: What makes Orforglipron different from Wegovy, Zepbound, and oral semaglutide Clinical trial results: 12.4% average weight loss over 72 weeks Why this oral pill doesn't require fasting or special timing like other oral GLP-1s The FDA accelerated review process and potential 2026 approval timeline Who benefits most: patients with needle phobia, injection site reactions, or seeking maintenance therapy What to expect regarding insurance coverage and access once approved   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

In this weekend deep dive, we break down how a 149-year-old pharma company from Indianapolis reinvented itself through GLP-1 weight-loss drugs like Mounjaro and Zepbound, overtook Novo Nordisk, and became one of Wall Street's hottest stocks. We cover Lilly's history from insulin to Prozac, the explosive growth of its weight-loss franchise, the coming pill that could unlock an even bigger market, and the risks ahead. Is the trillion-dollar valuation just the start, or is the stock already priced for perfection?

It's our 100th episode! I celebrate this milestone with Karen Bradley, NP, discussing the biggest wins, most common questions, and key themes from nearly two years of podcasting about women's sexual health and menopause.We dive into the FDA's recent decision to remove the boxed warning from vaginal estrogen a huge victory for women's health advocacy. This warning has prevented countless women from getting treatment for painful sex, recurrent UTIs, and other symptoms of genitourinary syndrome of menopause. I share a powerful story of a patient with breast cancer history who was denied hormone therapy by her oncology team, only to have them completely reverse course once the boxed warning was removed.The conversation covers the most frequently asked questions from listeners: Is it perimenopause or just stress? (It's both.) Why is my libido gone? (Biology, psychology, and life circumstances all play a role.) Why do I keep getting UTIs after sex? (Often it's vestibulodynia or changes in the vaginal microbiome from estrogen deficiency.) How do I talk to my partner about sex? (Communication is key, and sometimes you need a sex therapist to help.)We also discuss the reality of midlife weight gain, the role of GLP-1 medications like Wegovy and Zepbound, and why building muscle matters more than endless cardio. This episode is a celebration of how far we've come and a reminder that you don't have to suffer through menopause.Highlights:The FDA removed the boxed warning from vaginal estrogen—what this means for access to careThe biology behind midlife low libido and why it's not "all in your head"Why recurrent UTIs after sex might actually be vestibulodynia or vaginal microbiome changes.How to talk to your partner about sex when you've never had those conversationsThe truth about midlife weight gain and what hormones can and can't doGLP-1 medications: FDA approvals for weight loss, cardiovascular protection, MASH, and sleep apneaThank you for being here for 100 episodes. Honestly, there have been times I've wanted to stop, but then I get a DM from someone saying they heard something on the podcast that changed their care, or a patient tells me they finally found answers here. That's what keeps me going.The biggest way you can help me keep doing this work is simple: share this show with someone who needs it and hit subscribe. When you share an episode with a friend who's struggling, a family member who's been dismissed by doctors, or post about it on social media, you're helping me reach more women who deserve better care.Thank you for listening, for learning, and for advocating alongside me. Here's to the next 100.Get in Touch with Me: WebsiteInstagramYoutubeSubstack

Before we all slip into our cozy clothes and head toward the candied yams, I wanted to drop in with a quick Thanksgiving episode and a little love note from my heart to yours.Today, I'm sharing what I'm truly grateful for this season: you. Thank you for listening, for hanging with me through the messy seasons, the comebacks, the pauses, the growth, and all the moments in between. This community means more to me than I can ever put into words.I'm also talking about the real-life chaos of the holidays, the emotional weight many of us carry into this week, and some gentle reminders about food, body image, and giving yourself permission to just be you. You don't need to earn your Thanksgiving meal. You don't need to restrict. You don't need to go overboard. You're allowed to enjoy your plate, be present with your people, and let go of the guilt that diet culture tries to hand you.Take what you need, leave what you don't, and know that you're not alone.Wishing you a happy Thanksgiving filled with yummy food, core memories, and zero shame. I'm so grateful for you. 

New weight loss drugs may portend end of “Fat Acceptance” movement; Celebs and Southerners embrace GLP-1s; Trump clears path for more access to diet drugs; Mid- and late-life exercise slash dementia risk; “Ethicists” urge more tick-borne meat allergy to save planet—as alpha-gal syndrome claims first fatality; What's wrong with the melatonin study that claims it leads to heart failure? How to detox 9-11 first-responders? Can weekend warriors obtain same benefits as regular exercisers? 

In this conversation, Gianna discusses the role of GLP-1 medications in weight management, emphasizing that they are tools to support individuals in their health journeys rather than shortcuts. She highlights the importance of building habits and how GLP-1s can reduce resistance in the body, making it easier to achieve health goals.TakeawaysGLP-1s are tools that enhance the effectiveness of your efforts.They help build habits without constant struggle.The use of GLP-1s is not a shortcut but a strategic change.They support the body's processes to function more easily.Feeling your best is achievable with the right support.Weight management requires personal effort alongside medication.GLP-1s can reduce friction in health journeys.Building habits is crucial for long-term success.The relief of effective strategies can be rewarding.Support from GLP-1s can lead to better health outcomes.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor field your most urgent metabolic health questions—exploring care advocacy, novel drug use, lab results, and how to filter fact from fiction in the TikTok age. Dr. Cooper offers clinical clarity, real-world perspective, and actionable hope—with an emphasis on what truly matters for your long-term health and energy.Hear from listeners experiencing real breakthroughs (and challenges) with GLP-1s, get tips for navigating confusing cholesterol results, and learn why self-advocacy and good science matter more than credentials or hype. This is not a quick-fix episode; it's real metabolic medicine, mythbusting, and grounded encouragement for your health journey.Key Questions AnsweredWhat labs and scores best assess your true metabolic risk—and how do you make sense of fasting glucose, glucose-insulin ratio (GIR), and FIB-4?How can you find a medical provider who'll actually give you the time and attention metabolic care requires?Why do GLP-1s benefit more than weight loss alone? Listeners report help with sleep apnea, inflammation, and food noise—what does the science say?How should you reintroduce carbs after restriction, and what's the safest way to monitor (beyond A1C)?What's up with rising cholesterol on Zepbound, and when do you worry?Does serotonin syndrome relate to GLP-1s? (Short answer: No—Dr. Cooper explains why.)What are the dangers of “GLP-1 microdosing” as pushed by social media, and what happens when influencers overstep good science?Key TakeawaysCare that cares: The best doctor isn't always the most credentialed—find someone, MD, NP, or PA, who takes your questions seriously and goes deeper than the surface. Labs that matter: Fasting glucose, insulin, GIR, HbA1c, plus advanced lipid testing (CardioIQ, NMR) are critical for uncovering hidden risk—not just chasing numbers. GLP-1s act broadly: Listeners see gains in sleep, inflammation, and appetite regulation. These benefits are real, not just anecdotal, and Dr. Cooper shares the clinical rationale. Smart fueling, even on GLP-1s: If you lack hunger cues, “mechanical eating” prevents under-fueling and cellular stress—especially important for maintaining muscle and metabolism. Rethinking “microdosing”: TikTok trends are not medical advice—microdosing with black-market GLP-1s is unproven, poorly regulated, and potentially unsafe. Rely on trusted, legal medication sources only. Dr. Cooper's Actionable TipsRequest a full panel for metabolic health: ask your provider about fasting insulin, GIR, HbA1c, lipids, and FIB-4—even if you haven't been flagged as “at risk”. For those on GLP-1s: Don't skip meals; create a schedule with protein and fiber to avoid muscle loss and ensure micronutrient intake. Experiencing cholesterol shifts on medication? Ask for a breakdown (HDL, LDL, particle size) and consider advanced panels (CardioIQ, NMR) to better understand your risk. If reintroducing carbs after restriction, pair them with protein or fat and test glucose/insulin at intervals post-meal to personalize your plan. Avoid unregulated “microdosing” and buy only from reputable, FDA-approved outlets—protect your long-term health over quick fixes. Notable Quote“The most important thing is somebody who cares, not necessarily their degrees.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramAdvanced cholesterol testing: CardioIQ at Quest, NMR at LabCorpFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice. 

Pharma giant Eli Lilly manufactures the ingredients for its weight-loss drug Mounjaro and its diabetes drug Zepbound in Kinsale, Co Cork.The Irish Fiscal Advisory Council (Ifac) has found that the unprecedented surge in Irish exports this year (exports to the US rose by 153 per cent to €71bn between January and May) was almost entirely driven by shipments of these ingredients.Ifac tracked about €36.4bn of this export surge to Indianapolis, where Eli Lilly is headquartered and where it has several manufacturing sites.The jump in exports is expected to see the Irish economy expand by almost 11 per cent in GDP terms this year, which is almost certain to make it the fastest-growing advanced economy in the world in 2025.So with such an over-reliance on foreign direct investment, notably in the pharma sector, at a time of tariff threats and uncertainty, how vulnerable is Ireland?Irish Times economics correspondent Eoin Burke-Kennedy explains.Presented by Bernice Harrison. Produced by Suzanne Brennan and Andrew McNair. Hosted on Acast. See acast.com/privacy for more information.

Hey friends!

Broadcast from KSQD, Santa Cruz on 11-20-2025: Dr. Dawn discusses GLP-1 inhibitors like Zepbound and semaglutide showing unexpected benefits for addiction treatment beyond diabetes and weight loss. Patients in rehab report these drugs mute cravings for alcohol, cocaine, and cigarettes. Multiple studies show reduced substance abuse rates in users, with VA and NIH conducting trials examining brain activity and responses to triggers. With 80,000 annual drug overdose deaths and 48 million Americans having substance abuse disorders, these medications may revolutionize addiction treatment by dampening brain reward circuitry, though costs threaten healthcare budgets. A Stanford twin study found those twins assigned a vegan diet had substantially lower cholesterol, insulin, and body weight compared to their omnivore twins after several months, with LDL dropping 15mg, four pounds more weight loss, and 20% lower insulin. Dr. Dawn explains how a fungal disease decimating Central American frog populations caused 500% malaria increases in some areas. The fungus kills frogs by blocking skin electrolytes until hearts stop, eliminating tadpoles that eat mosquito larvae. Ecosystem collapses followed with algae blooms and snake population drops. She provides other examples showing how species losses affect human health, emphasizing the "one health" movement recognizing ecosystem health as fundamental to human wellbeing. An Australian study found people aged 70+ who listen to or play music regularly had 39% lower dementia rates, though causation remains uncertain. Princeton research shows music activates multiple brain regions simultaneously. Learning instruments increases gray matter, and musical memory remains intact in advanced dementia since it's stored separately from other memories. A caller discusses how modern screen-based activities provide less multisensory engagement than past social experiences like dances. Another caller describes Grover's disease causing persistent itchy skin with no known cause. Dr. Dawn recommends an elimination diet removing common allergens for one month, then reintroducing individually to identify food sensitivities triggering immune responses. Dr. Dawn explains xenotransplantation advances with genetically edited pigs beginning full-scale kidney transplant trials. Companies use CRISPR to disable genes causing immune rejection and insert human genes promoting immune tolerance. With only 10% of global kidney patients receiving organs, these could provide unlimited supply. Other innovations include kidneys with thymus tissue to teach immune tolerance and external pig liver systems as transplant bridges. She concludes noting research showing female dogs remember and prefer humans who demonstrate competence at tasks, while male dogs show no preference.

You've done the meal prep, the steps, the Peloton rides after bedtime stories—yet the scale is not "scaling". Now everybody from your group chat to Serena Williams is talking about “the shot.” In this episode, Dr. Stephane Hack, MD, MPH, breaks down GLP-1 medications (like Ozempic, Wegovy, and Zepbound) in plain language: what they are, how they work, who they're really for, and what risks often get glossed over. We'll talk motherhood, metabolism, perimenopause, endometriosis, fertility, and the pressure to “snap back". Whether you're a busy professional juggling work, marriage, kids, or just trying to feel at home in your own body again, this conversation is your judgment-free zone to get informed before you decide what's next for your body.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor dive into your burning questions from around the world—exploring misunderstood metabolic problems, hard-won solutions for real people, and the science behind the headlines. From “selfish brain” physiology to the rollercoaster of insurance and medication access, Dr. Cooper brings clinical clarity and practical hope.Hear real-world listener stories, get advice on tuning your metabolic health, and learn why personalization—not “calories in, calories out”—leads to better outcomes. This is no silver bullet show: it's metabolic medicine, mythbusting, and science-backed encouragement for your journey.Key Questions AnsweredWhat is the “selfish brain” and how does it really impact blood sugar and diabetes risk?Why do GLP-1 medications affect stamina and hunger, and how should you fuel your body if you're using them?If insurance pulls coverage for medications like Ozempic or Zepbound, what are your practical, safe, and affordable options?How do metabolic markers, medication “cocktails,” and genetic testing shape Dr. Cooper's individualized care—and can you taper off meds and maintain results?What does “normal” blood sugar look like after meals, and how do you distinguish trends from outliers?Key TakeawaysMetabolism is complex—individualized care is essential. Diabetes, hypoglycemia, and insulin resistance all have personal causes and require testing like the Mixed Meal Tolerance Test to solve—not one-size-fits-all advice. GLP-1s require smart fueling. Many experience reduced stamina on these medications. Dr. Cooper recommends upping both complex and simple carbs pre-exercise and consulting with a registered dietitian if fatigue persists. Insurance coverage is a challenge—but not the end. Generic options (like liraglutide/Victoza via Mark Cuban Cost Plus Drugs), manufacturer programs, and “cocktail” regimens can support continued progress, even if you lose access to top-brand GLP-1s. Feedback loops & genetics drive lasting outcomes. While some patients can successfully—slowly—taper medications, most with metabolic dysfunction will need long-term support. “Clean eating” alone rarely reverses underlying feedback loop glitches. Monitoring is powerful. Using blood sugar monitors (especially for diabetics) can demystify meal spikes and help fine-tune nutrition and medication timing. Personal stories reflect broader truths. Listeners share struggles and solutions, reinforcing that metabolic health spans medication, motivation, and mindset.Dr. Cooper's Actionable TipsAlways dig deeper with testing—not just A1C but also post-meal spikes via the Mixed Meal Tolerance Test.If you're prescribed a GLP-1 and struggle with energy, increase carb intake safely and talk to a doctor about medication adjustment. For lost coverage, stick to FDA-approved sources: Lilly Direct for Zepbound, Novocare for Wegovy, and Mark Cuban for generics. Don't risk unregulated online compounds. Recognize the difference between generalized “healthy” habits and targeted strategies that actually move your biomarkers.Stay consistent and compassionate—focus on small improvements over extremes and absolutes.Notable Quote“The metabolism is regulated by a feedback loop…when you introduce outside hormone forms, you strengthen signals to favor fuel utilization over energy conservation.”— Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramGeneric medication access: Mark Cuban Cost Plus DrugsZepbound direct: Lilly DirectAdditional info: Novocare for WegovyFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Drugs like Ozempic and Zepbound have revolutionized weight loss. And starting next year, the drugs are going to become more affordable for Americans because of a deal struck with pharmaceutical companies by the Trump administration.Eshe Nelson, who covers economics and business news, explains how the change has its origins in a huge business blunder from the creator of Ozempic, Novo Nordisk.Guest: Eshe Nelson, a reporter for The New York Times based in London, where she covers economics and business news.Background reading: How Ozempic's maker lost its shine after creating a wonder drug.What Trump's new drug pricing deal means for people with obesity.Photo: Sergei Gapon/Agence France-Presse — Getty ImagesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

The Friday Five for November 14, 2025: iPhone Pocket Brings Back… Pockets. CMS Rural Health Transformation Program Government Shutdown Update Most-Favored Nation Drug Pricing CMS GENEROUS Model   Get Connected:

In Part 1 we looked at the basics and early research around GLP-1s for weight loss and muscle loss. In part 2 we looked at recent research around the newest GLP-1 weight loss drugs, tirzepatide (Zepbound) and semaglutide (Wegovy).In this final part of the series we are going to talk about the justifications/excuses/spin that are happening around the loss of lean muscle mass on GLP-1s. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

After taking some much-needed time off before, during, and after our family cruise, I'm finally back behind the mic — and whew, it's been a minute! In this episode, I'm catching you up on life, how hard it can be to get back into your rhythm, and the lessons I learned along the way.This isn't just a vacation recap. It's a reminder that life is happening right now. You can't wait until you lose the weight or have it all together to make memories. From cruise chaos to core memories, I'm sharing how “someday” never comes, why you should take the trip, and what going with the flow taught me about self-acceptance and joy.Plus, I'll share a few of my favorite Amazon outfit finds and cruise must haves that made the trip easier, cuter, and a little more glam (even in mom mode).

Welcome back to The Weight Loss Collab! In today's episode, bariatric surgeon and obesity medicine expert Dr. Dovec is diving deep into the world of GLP-1 medications—those popular injectables like Ozempic, Wegovy, Zepbound, and Mounjaro that everyone's been talking about. Whether you're fresh out of bariatric surgery, struggling with weight plateaus, have a lower or higher BMI, or you're just curious if these meds might be right for you, Dr. Dovec breaks down exactly how GLP-1s work, who benefits most, potential side effects, and how to personalize your treatment for the best results. Plus, she compared options like phentermine and Contrave, and gives real talk about surgery versus medication. If you're looking for up-to-date, honest guidance on weight loss medications and a supportive community cheering you on, this episode is packed with insights and actionable advice!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. If you've had bariatric surgery, you already know what it means to commit fully to your health.  But even with your best efforts, bodies adapt, hormones shift, and life adds its own complications. When weight begins to creep back, many people turn to GLP-1 medications for support, and that raises a crucial question: How well do GLP-1s actually work after bariatric surgery?I recently heard from a listener living this exact experience — someone who lost more than 200 pounds after gastric bypass and has now started Zepbound to address weight regain. Her story opens the door to an important conversation about why GLP-1 medications can behave differently in a post-bariatric body, why results may not mirror those of someone without surgical history, and how to redefine success when you've already achieved a significant transformation.ReferencesThe Obesity Guide: Behind the Curtain (Season 1)The Obesity Guide: Behind the Curtain (Season 2) - Includes access to the December 21-Day Challenge with daily coaching, actionable steps, and community support to end your year with momentum.Audio Stamps00:40 - Dr. Rentea shares a heartwarming reunion at the VA, reconnecting with former colleagues and reflecting on how far she's come in her weight loss journey.07:10 - Fan mail question: Does Zepbound (tirzepatide) work the same after gastric bypass surgery, and what weight loss results should you expect?09:11 - Why post-bariatric patients often respond better to GLP-1 medications and become "hyper responders" at lower doses.16:18 - Redefining success: why focusing on your relationship with food and sustainability matters more than hitting a specific weight loss percentage.17:48 - Common post-surgery pitfalls including grazing patterns, excessive step counting, and neglecting body composition tracking.20:42 - Information on the December 21-Day Challenge and upcoming 30/30 program rounds.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com ✨ Season 2 of Behind the Curtain is officially live! ✨ You can join the season on its own or take it a step further by opting into the live 21-Day Challenge with Dr. Rentea, running December 1–21—the perfect way to finish the year strong and head into the holidays with momentum.

In this powerful episode, I will break down one of the biggest developments in obesity and diabetes treatment in U.S. history. Two major pharmaceutical companies - Eli Lilly and Novo Nordisk - have reached a groundbreaking agreement with the administration that will drastically reduce the prices of popular medications like Wegovy, Ozempic, and Zepbound. This pricing model could transform how obesity medications are covered, distributed, and accessed across Medicare, Medicaid, and direct-to-consumer platforms. Tune in to learn what this new deal means for patients, healthcare providers, and public health overall—and why it's being called a game changer for people struggling with obesity and related health conditions. Episode Highlights: Major price cuts announced for Wegovy, Ozempic, and Zepbound under a new federal deal   Medicare to cover obesity drugs for the first time through a five-year pilot program   Medicaid given the option to join discounted pricing starting 2026   Team Rx launches a direct-to-consumer model cutting out costly middlemen   Lower cash prices for GLP-1 medications and upcoming oral versions   Eli Lilly and Novo Nordisk to invest billions in U.S. manufacturing   Program expected to improve access, affordability, and supply of obesity and diabetes meds   Ongoing push for the Treat and Reduce Obesity Act to expand national coverage   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

You've heard of Ozempic Face.  And Ozempic Vulva.  Now there's Ozempic Breast!  That's the loss of breast volume and sagging of the breast after the use of GLP-1 drugs like Ozempic and Zepbound.  On this show, we discuss how breast lifting after weight loss or after pregnancy can restore a beautiful shape to the breast....without the use of implants.  And we discussed the recent FDA warnings to 18 websites selling botulinum toxins on the web to unsuspecting people.  Tune in!

In Part 1 we looked at an early study of GLP1 drugs and muscle loss. Today we'll look at two more recent studies, one for Eli Lilly's drug tirzepatide and one for Novo Nordisk's drug semaglutide. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Andrew Walworth, Tom Bevan and Carl Cannon discuss new polling on candidate preferences for the 2028 presidential nomination for both parties, and this morning's reporting from Politico that Secretary of State Marco Rubio is telling close associates that he believes Vice President JD Vance is the frontrunner for the Republican nomination. Then, they talk about the role of energy prices in last Tuesday's election, and President Donald Trump's new agreement with pharmaceutical manufacturers to sell GLP-1 products like Wegovy and Zepbound at discounted prices to Medicare and Medicaid recipients. Then finally, the guys discuss the jury verdict in Washington, DC of the former Justice Department employee who threw a sandwich at a federal officer in protest last August. Plus, this week's “You Cannot Be Serious” stories. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Mazel morons! Today Ben's feeling skinny (thank you, Zepbound), Josh's dishing gym wisdom, and together we unpack Ozempic science, LA beauty standards, overpriced popcorn, dopamine traps, why you should never pickle on vacation, and why LA makes everyone just a little hotter. We also confess our screen-time addictions, talk dad life, and end with a What Are Ya Nuts that involves Target, 20 grand in cash, and questionable decision-making. Love ya! Leave us a voicemail here!Follow us on Instagram and TikTok! Sponsors:Caraway - Plus, if you visit Carawayhome.com/GOOD10 you can take an additional 10% off your next purchase.goodwipes - Just buy a pack at Target, Walmart, Kroger—or your local store—then head to goodwipes.com/GOODGUYS, text them your receipt and get reimbursed!Skims - Shop SKIMS Mens at SKIMS.comQuo - Quo is offering my listeners 20% off your first 6 months at Quo.com/goodguysOlipop - Get $2 off a 4-pack of OLIPOP- Works on any flavor of 4-pack, including Spongebob, any retailer at drinkolipop.com/GOODGUYSHome Chef - For a limited time, Home Chef is offering my listeners FIFTY PERCENT OFF and free shipping for your first box PLUS free dessert for life! Go to HomeChef.com/GOODGUYSPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In the latest episode of The Mom Wars, Bethany talks us through her weight-loss journey with Zepbound, and the girls discuss the latest postpartum body discourse.

Trump unveils deal to expand coverage and lower costs on obesity drugs Wegovy and Zepbound. AP's Lisa Dwyer reports.

Bonus Episode for Nov. 4. The weight-loss-drug arms race is only heating up, as Novo Nordisk attempts to snatch drugmaker Metsera away from Pfizer. But can either company compete with Zepbound seller Eli Lilly? WSJ reporter Peter Loftus discusses what earnings from Big Pharma, including AbbVie, Bristol Myers Squibb and Merck, say about the future of the industry and how companies are responding to President Trump's drug-pricing plans, including TrumpRx. WSJ Heard on the Street columnist David Wainer hosts this special bonus episode of What's News in Earnings, where we dig into companies' earnings reports and analyst calls to find out what's going on under the hood of the American economy. Sign up for the WSJ's free Markets A.M. newsletter. Further Reading: Novo Nordisk Sweetens Offer for Metsera - WSJ Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal Why Pfizer Can Still Prevail in the Obesity Fight With Novo Nordisk The Day Pharma's Weight-Loss Gold Rush Intensified Pfizer Profit Falls Amid Lower Covid-19 Drug Demand Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera Novo Nordisk to Shake Up Board After Obesity-Market Challenges Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings AbbVie Lifts Profit Outlook as Sales Rise Bristol Myers Squibb Profit Soars, Raises Revenue Guidance Merck Profit Rises on Strong Keytruda Demand GSK Lifts Guidance After Specialty Medicines Boost Sales Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise J&J Lifts Full-Year Sales Outlook, Fueled by Pharma, Med-Device Gains Learn more about your ad choices. Visit megaphone.fm/adchoices

Exclusive OTP Savings HTTPS://www.otplinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We've all heard the headlines about GLP-1s. The miracle weight-loss meds. The quick fix. The controversy.But what does it actually feel like to live it?Nicole has been my client for 18 months and a year ago she started Zepbound  and has lost nearly 60 pounds. But that's not the only story.The story is about what happened underneath the weight loss—the food noise that finally quieted, the skill work that still had to happen even with the meds, and the life she's living now that no diet ever gave her.What we talk about:What “food noise” really feels like — and what happens when it finally goes quietThe difference between biological change and behavioral changeWhy the meds don't replace the work — they create space for itThe “finish your plate” brain that doesn't disappear overnightHow Nicole's body image is evolving while she's still losing weightConnect with JordanaFind me on InstagramSign up for my Monday newsletter with lots of nutrition, body image and mindset tipsSchedule a free discovery call to talk more about working together Listen to more episodes of The Diet Diaries

A gain in same-store sales wasn't enough to reel investors back into Starbucks (SBUX). Diane King Hall says a lack of outlook had many investors scratching their heads. Eli Lilly (LLY) rallied after showing strength in its Mounjaro and Zepbound weight-loss drugs. Estée Lauder (EL) posted a profit that Diane King Hall calls a "sigh of relief" for investors.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

In the last few years, GLP-1 weight-loss drugs like Ozempic and Zepbound have been radically reshaping the people's lives, changing appetites and health.But the drugs also have the power to affect other parts of consumers' lives, including their romantic relationships.Lisa Miller, who writes about health for The New York Times, tells the story of how these drugs upended one couple's marriage.Guest: Lisa Miller, a domestic correspondent for the Well section who writes about personal and cultural approaches to physical and mental health.Background reading: Weight-loss drugs have lesser-known side effects on relationships.Photo: Katherine Wolkoff for The New York TimesFor more information on today's episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.  Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.